These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 16984067)
1. Priority setting for research in health care: an application of value of information analysis to glycoprotein IIb/Illa antagonists in non-ST elevation acute coronary syndrome. Philips Z; Claxton KP; Palmer S; Bojke L; Sculpher MJ Int J Technol Assess Health Care; 2006; 22(3):379-87. PubMed ID: 16984067 [TBL] [Abstract][Full Text] [Related]
2. Glycoprotein IIb/IIIa blockers in non-ST elevation acute coronary syndromes: only for well defined subgroups or a therapeutic option for all patients? Verheugt FW J Thromb Thrombolysis; 2003 Apr; 15(2):81-4. PubMed ID: 14618073 [TBL] [Abstract][Full Text] [Related]
3. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both? Silva MA; Donovan JL; Gandhi PJ; Volturo GA Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling. Robinson M; Palmer S; Sculpher M; Philips Z; Ginnelly L; Bowens A; Golder S; Alfakih K; Bakhai A; Packham C; Cooper N; Abrams K; Eastwood A; Pearman A; Flather M; Gray D; Hall A Health Technol Assess; 2005 Jul; 9(27):iii-iv, ix-xi, 1-158. PubMed ID: 16022802 [TBL] [Abstract][Full Text] [Related]
5. Managing acute coronary syndrome: evidence-based approaches. Spinler SA Am J Health Syst Pharm; 2007 Jun; 64(11 Suppl 7):S14-24. PubMed ID: 17519441 [TBL] [Abstract][Full Text] [Related]
6. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. Alexander JH; Harrington RA Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986 [TBL] [Abstract][Full Text] [Related]
7. The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients. Tricoci P; Peterson ED J Interv Cardiol; 2006 Oct; 19(5):449-55. PubMed ID: 17020570 [TBL] [Abstract][Full Text] [Related]
9. Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention. Januzzi JL; Cannon CP; Theroux P; Boden WE Am Heart J; 2003 Nov; 146(5):764-74. PubMed ID: 14597924 [TBL] [Abstract][Full Text] [Related]
10. Risks and benefits of glycoprotein IIb/IIIa antagonists in acute coronary syndrome. Latour-Pérez J Ann Pharmacother; 2001 Apr; 35(4):472-9. PubMed ID: 11302412 [TBL] [Abstract][Full Text] [Related]
11. Glycoprotein IIb/IIIa antagonists in acute coronary syndromes: where are we now? Maree A; Fitzgerald DJ Semin Vasc Med; 2003 Nov; 3(4):385-90. PubMed ID: 15199445 [TBL] [Abstract][Full Text] [Related]
12. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type]. Galli M; Maggioni AP; Vassanelli C; Tavazzi L Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377 [TBL] [Abstract][Full Text] [Related]
13. Intravenous glycoprotein IIb/IIIa inhibition in non-ST segment elevation acute coronary syndromes. Chew DP; Roffi M; Topol EJ Prog Cardiovasc Dis; 2001; 44(3):195-206. PubMed ID: 11727277 [TBL] [Abstract][Full Text] [Related]
14. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale. Giugliano RP; Newby LK; Harrington RA; Gibson CM; Van de Werf F; Armstrong P; Montalescot G; Gilbert J; Strony JT; Califf RM; Braunwald E; Am Heart J; 2005 Jun; 149(6):994-1002. PubMed ID: 15976780 [TBL] [Abstract][Full Text] [Related]
15. Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selection. Atwater BD; Roe MT; Mahaffey KW Drugs; 2005; 65(3):313-24. PubMed ID: 15669877 [TBL] [Abstract][Full Text] [Related]
16. Platelet glycoprotein IIb/IIIa inhibitor therapy in non-ST segment elevation acute coronary syndromes. Elmouchi DA; Bates ER Minerva Cardioangiol; 2003 Oct; 51(5):547-60. PubMed ID: 14551523 [TBL] [Abstract][Full Text] [Related]
17. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Lincoff AM; Harrington RA; Califf RM; Hochman JS; Guerci AD; Ohman EM; Pepine CJ; Kopecky SL; Kleiman NS; Pacchiana CM; Berdan LG; Kitt MM; Simoons ML; Topol EJ Circulation; 2000 Sep; 102(10):1093-100. PubMed ID: 10973836 [TBL] [Abstract][Full Text] [Related]